Cargando…
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial
Active surveillance (AS) is a widely recognized and utilized option by which prostate cancer patients with less aggressive tumors on diagnosis defer immediate traditional conventional therapy (surgery, radiation) and undergo close monitoring by a physician for any clinical or pathologic changes. The...
Autores principales: | Moyad, Mark A, Scholz, Mark C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106964/ https://www.ncbi.nlm.nih.gov/pubmed/25157338 http://dx.doi.org/10.2147/RRU.S63136 |
Ejemplares similares
-
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
por: Shore, Neal D., et al.
Publicado: (2022) -
Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer
por: Lara, Pedro C., et al.
Publicado: (2022) -
Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016) -
Active surveillance in intermediate risk prostate cancer: is it safe?
por: Henk, G. van der Poel, et al.
Publicado: (2016) -
Active surveillance in intermediate risk prostate cancer: is it safe?
por: Krishnananthan, Nishanth, et al.
Publicado: (2016)